The aim of this study was to investigate the associations between dapagliflozin‐mediated
reductions in body weight and reductions in glycated haemoglobin (HbA1c) and blood …

Aims To investigate changes in glycated hemoglobin (HbA1c), body weight (BW), and
systolic blood pressure (SBP) in type 2 diabetes (T2D) primary care patients initiating …

Hypertension and type 2 diabetes mellitus (T2DM) are risk factors for cardiovascular
disease. Dapagliflozin improves glycemic control and systolic blood pressure (SBP) in …

Aims To investigate prescribing patterns and effect of dapagliflozin among individuals with
T2DM using UK primary care data. Methods Adult patients with T2DM initiating dapagliflozin …

Introduction The present study aimed to describe characteristics of patients with type 2
diabetes (T2D) in UK primary care initiated on dapagliflozin, post-dapagliflozin changes in …

Background: In randomized clinical trials, dapagliflozin has been shown to improve glycemic
control, weight, and blood pressure. However, there is little real-world evidence of the …

Context: Dapagliflozin, a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor,
reduces hyperglycemia in patients with type 2 diabetes mellitus (T2DM) by increasing …

Background Treatment of type 2 diabetes (T2D) should aim at preventing or delaying
complications through the control of glycaemia and cardiovascular risk factors. We herein …

Objectives Sodium-glucose cotransporter 2 inhibitors (SGLT2i) modulate lipid metabolism
and improve cardiovascular morbidity and mortality in patients with type 2 diabetes mellitus …

Introduction Maintenance of drug efficacy and safety over the long term is important to
investigate for progressive conditions like type 2 diabetes mellitus (T2DM). This study aimed …